PRME
Prime Medicine, Inc.
Industry
Biotechnology
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
2.95
Mkt cap
378M
Volume
1.2M
High
3.00
P/E Ratio
-1.40
52-wk high
9.86
Low
2.81
Div yield
N/A
52-wk low
2.81

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.